spacer gif spacer gif spacer gif spacer gif ARCHIVE ANNOUNCEMENT! spacer gif
QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    

First published online 13 April 2005
doi: 10.1242/dev.01824

Development 132, 2263-2272 (2005)
Published by The Company of Biologists 2005
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dev.01824v1
132/10/2263    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wildonger, J.
Right arrow Articles by Mann, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wildonger, J.
Right arrow Articles by Mann, R. S.

The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor

Jill Wildonger1 and Richard S. Mann1,2,*

1 Center for Neurobiology and Behavior, Columbia University Medical School, New York, NY 10032, USA
2 Department of Biochemistry and Molecular Biophysics, Columbia University Medical School, New York, NY 10032 USA

* Author for correspondence (e-mail: rsm10{at}columbia.edu)

Accepted 10 March 2005

The human translocation (t8;21) is associated with ~12% of the cases of acute myelogenous leukemia. Two genes, AML1 and ETO, are fused together at the translocation breakpoint, resulting in the expression of a chimeric protein called AML1-ETO. AML1-ETO is thought to interfere with normal AML1 function, although the mechanism by which it does so is unclear. Here, we have used Drosophila genetics to investigate two models of AML1-ETO function. In the first model, AML1-ETO is a constitutive transcriptional repressor of AML1 target genes, regardless of whether they are normally activated or repressed by AML1. In the second model, AML1-ETO dominantly interferes with AML1 activity by, for example, competing for a common co-factor. To discriminate between these models, the effects of expressing AML1-ETO were characterized and compared with loss-of-function phenotypes of lozenge (lz), an AML1 homolog expressed during Drosophila eye development. We also present results of genetic interaction experiments with AML1 co-factors that are not consistent with AML1-ETO behaving as a dominant-negative factor. Instead, our data suggest that AML1-ETO acts as a constitutive transcriptional repressor.

Key words: AML1 (RUNX1), AML1-ETO, MTG8, Lozenge, CBFß, Drosophila eye, RUNX1T1




This article has been cited by other articles:


Home page
 BloodHome page
C. K. Cheng, L. Li, S. H. Cheng, K. M. Lau, N. P. H. Chan, R. S. M. Wong, M. M. K. Shing, C. K. Li, and M. H. L. Ng
Transcriptional repression of the RUNX3/AML2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia
Blood, October 15, 2008; 112(8): 3391 - 3402.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Choi, K. E. Elagib, L. L. Delehanty, and A. N. Goldfarb
Erythroid Inhibition by the Leukemic Fusion AML1-ETO Is Associated with Impaired Acetylation of the Major Erythroid Transcription Factor GATA-1.
Cancer Res., March 15, 2006; 66(6): 2990 - 2996.
[Abstract] [Full Text] [PDF]


© The Company of Biologists Ltd 2005